Pharmaceuticals company Bajaj Healthcare announced Q3FY26 results Revenue from Operations: Rs 1,612.2 million against Rs 1,227.9 million during Q3FY25, change 31.3%. EBITDA: Rs 323.3 million against Rs 240.1 million during Q3FY25, change 34.6%. EBITDA Margin: 19.8% for Q3FY26. PAT: Rs 156.7 million against Rs 117.2 million during Q3FY25, change 33.7%. Anil Jain, Managing Director said: “Amid global volatility and geopolitical uncertainty, our Q3FY26 results highlight the resilience of our operations and disciplined execution. Revenue grew 31% YoY, supported by a robust 35% increase in EBITDA. A key driver of this performance was the strong growth in API exports, which more than doubled compared to last year. This momentum has translated into a 30% increase in PAT for the nine months ended December 2025, reaffirming our ability to scale rapidly in regulated markets. Our domestic API business recorded growth of 15%. While pricing pressure persists across the industry, our continued focus on driving steady volume growth is yielding results. The increased focus on the formulations business is contributing meaningfully and is scaling well. Our CDMO business is also gaining traction with supplies ramping up significantly, underscoring our ability to integrate seamlessly with global innovators, while building a scalable and diversified growth engine for the future. We continue to advance our CNS portfolio, with recently secured CDSCO approval to conduct trials for Suvorexant and ongoing Phase III trials for Cenobamate. With the launch of Magtein this quarter, we have further strengthened our offerings in the segment. Other molecules are also scaling up, adding depth to the portfolio. Together, these initiatives highlight our focus on high-potential therapeutic areas and reinforce our commitment to addressing unmet global needs. On the regulatory front, we continue to strengthen our global compliance framework and advance product registrations across key geographies. Our focus remains on expanding our presence in regulated markets and aligning our pipeline with high-value therapeutic areas that offer long-term growth potential. As we look ahead, our business mix will increasingly shift toward exports anchored by our strong API foundation and growing credibility in regulated markets. We remain focused on sustaining cost competitiveness while securing key approvals that broaden our global reach. With continued investments in R&D;, ongoing capex, and the expertise of our management team, we are confident of achieving sustainable and scalable growth. We remain committed to creating long-term value for the healthcare ecosystem and all stakeholders.” Result PDF